Lindsay B. Hough
Center for Neuropharmacology and Neuroscience
Albany Medical College MC-136
47 New Scotland Ave.
Albany
Name/email consistency: high
- Effects of acetylenic epoxygenase inhibitors on recombinant cytochrome p450s. Vanalstine, M.A., Hough, L.B. Drug Metab. Dispos. (2011)
- H3 receptors and pain modulation: peripheral, spinal, and brain interactions. Hough, L.B., Rice, F.L. J. Pharmacol. Exp. Ther. (2011)
- Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic. Hough, L.B., Nalwalk, J.W., Yang, J., Conroy, J.L., VanAlstine, M.A., Yang, W., Gargano, J., Shan, Z., Zhang, S.Z., Wentland, M.P., Phillips, J.G., Knapp, B.I., Bidlack, J.M., Zuiderveld, O.P., Leurs, R., Ding, X. Pain (2011)
- Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms. Hough, L.B., Svokos, K., Nalwalk, J.W. Brain Res. (2009)
- CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist. Hough, L.B., Nalwalk, J.W., Phillips, J.G., Kern, B., Shan, Z., Wentland, M.P., de Esch, I.J., Janssen, E., Barr, T., Stadel, R. Neuropharmacology (2007)
- Antinociceptive activity of furan-containing congeners of improgan and ranitidine. Hough, L.B., Menge, W.M., van de Stolpe, A.C., Nalwalk, J.W., Leurs, R., de Esch, I.J. Bioorg. Med. Chem. Lett. (2007)
- Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic. Hough, L.B., de Esch, I.J., Janssen, E., Phillips, J., Svokos, K., Kern, B., Trachler, J., Abood, M.E., Leurs, R., Nalwalk, J.W. Neuropharmacology (2006)
- Pain-relieving drugs and the brain histaminergic system: multiple analgesic mechanisms from histamine, improgan and cimetidine. Hough, L.B., Nalwalk, J.W., Svokos, K., Leurs, R., Timmermann, H. Inflamm. Res. (2004)
- Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors. Hough, L.B., Nalwalk, J.W., Stadel, R., Timmerman, H., Leurs, R., Paria, B.C., Wang, X., Dey, S.K. J. Pharmacol. Exp. Ther. (2002)
- Significance of GABAergic systems in the action of improgan, a non-opioid analgesic. Hough, L.B., Nalwalk, J.W., Leurs, R., Menge, W.M., Timmerman, H. Life Sci. (2001)
- Antinociceptive activity of derivatives of improgran and burimamide. Hough, L.B., Nalwalk, J.W., Leurs, R., Menge, W.M., Timmerman, H. Pharmacol. Biochem. Behav. (2000)
- Pharmacokinetic characterization of the indole alkaloid ibogaine in rats. Hough, L.B., Bagal, A.A., Glick, S.D. Methods. Find. Exp. Clin. Pharmacol (2000)
- A third life for burimamide. Discovery and characterization of a novel class of non-opioid analgesics derived from histamine antagonists. Hough, L.B., Nalwalk, J.W., Barnes, W.G., Leurs, R., Menge, W.M., Timmerman, H., Wentland, M. Ann. N. Y. Acad. Sci. (2000)
- Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice. Hough, L.B., Nalwalk, J.W., Chen, Y., Schuller, A., Zhu, Y., Zhang, J., Menge, W.M., Leurs, R., Timmerman, H., Pintar, J.E. Brain Res. (2000)
